FY2026 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Cut by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Leerink Partnrs reduced their FY2026 earnings estimates for Axsome Therapeutics in a research report issued on Monday, May 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $1.60 for the year, down from their previous forecast of $1.85. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2027 earnings at $7.95 EPS and FY2028 earnings at $11.40 EPS.

Several other analysts also recently weighed in on AXSM. Citigroup cut their price target on Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday. Truist Financial reissued a “buy” rating and set a $150.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Axsome Therapeutics in a report on Tuesday. Guggenheim raised their price target on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Finally, Royal Bank of Canada upped their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $121.92.

Axsome Therapeutics Stock Down 2.6 %

NASDAQ:AXSM opened at $73.68 on Wednesday. Axsome Therapeutics has a 1-year low of $55.02 and a 1-year high of $98.40. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.63 and a quick ratio of 3.52. The firm’s 50-day moving average price is $73.84 and its 200-day moving average price is $75.72. The company has a market capitalization of $3.50 billion, a PE ratio of -11.55 and a beta of 1.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.48. The company had revenue of $71.53 million during the quarter, compared to analysts’ expectations of $70.38 million. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%.

Insider Activity

In related news, COO Mark L. Jacobson sold 24,662 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares of the company’s stock, valued at $8,416,693.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The disclosure for this sale can be found here. Insiders own 24.50% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Washington Trust Advisors Inc. purchased a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $26,000. Fifth Third Bancorp grew its holdings in Axsome Therapeutics by 100.0% during the 3rd quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock valued at $28,000 after buying an additional 200 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Axsome Therapeutics by 5,550.0% during the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after buying an additional 777 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Axsome Therapeutics by 110.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,204 shares of the company’s stock worth $84,000 after buying an additional 633 shares in the last quarter. Finally, Janiczek Wealth Management LLC bought a new position in shares of Axsome Therapeutics during the first quarter worth $97,000. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.